Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

April 30, 2015

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

inhaled carbon monoxide

The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.

OTHER

Oxygen

Room air oxygen concentrations will be administered as placebo

Trial Locations (8)

10032

Columbia University, New York

48109

University of Michigan, Ann Arbor

60612

University of Illinois Chicago, Chicago

60637

University of Chicago, Chicago

70112

Tulane University, New Orleans

94143

University of California San Francisco, San Francisco

98195

University of Washington, Seattle

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

University of California, San Francisco

OTHER

collaborator

University of Chicago

OTHER

collaborator

University of Illinois at Chicago

OTHER

collaborator

University of Michigan

OTHER

collaborator

Columbia University

OTHER

collaborator

Tulane University

OTHER

collaborator

University of Washington

OTHER

lead

Brigham and Women's Hospital

OTHER

NCT01214187 - Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter